A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of NL003 in Subject With Critical Limb Ischemia

Trial Profile

A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of NL003 in Subject With Critical Limb Ischemia

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Mar 2015

At a glance

  • Drugs Hepatocyte growth factor gene therapy (Primary)
  • Indications Peripheral arterial disorders; Ulcer
  • Focus Therapeutic Use
  • Sponsors Beijing Northland Biotech
  • Most Recent Events

    • 23 Mar 2015 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov record.
    • 08 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top